Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc.INDV · Entity 4040 | Director | May 13, 2026 | May 14, 2026 |
| MEDICINES CO /DEMDCO · Entity 152552 | President and COO | March 01, 2017 | March 02, 2017 |
| Protara Therapeutics, Inc.PRTO · Entity 6203 | Director | June 08, 2018 | June 11, 2018 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director · President and CEO | February 01, 2021 | February 03, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Indivior Pharmaceuticals, Inc.
Report date May 13, 2026 · Filed May 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,100 |
Reported balance
After 2026-05-13 transaction · row 1
1 source rowRow 1 · 2026-05-13 · Grant · Acquired 6,518 · Balance 12,100 F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date.
MEDICINES CO /DE
Report date March 01, 2017 · Filed March 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 11,386 |
Reported balance
After 2017-03-01 transaction · row 1
1 source rowRow 1 · 2017-03-01 · Grant · Acquired 11,386 · Balance 11,386 F1: Shares of restricted stock vest in 25% increments on each anniversary of the date of grant, until fully vested. |
| Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.70 · Expires 2027-03-01 | Direct | 70,265 |
Reported balance
After 2017-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-03-01 · Grant · Acquired 70,265 · Balance 70,265 F2: The option vests in forty-eight equal installments beginning April 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares of restricted stock vest in 25% increments on each anniversary of the date of grant, until fully vested.
F2: The option vests in forty-eight equal installments beginning April 1, 2017.
Protara Therapeutics, Inc.
Report date June 08, 2018 · Filed June 11, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2028-06-07 | Direct | 12,700 |
Reported balance
After 2018-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-08 · Grant · Acquired 12,700 · Balance 12,700 F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders.
Scholar Rock Holding Corp
Report date February 01, 2021 · Filed February 03, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,000 |
Reported balance
After 2021-02-01 transaction · row 1
1 source rowRow 1 · 2021-02-01 · Grant · Acquired 42,000 · Balance 42,000 F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest and become exercisable annually over four years, subject to a continued service relationship with the Issuer on such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $58.93 · Expires 2031-02-01 | Direct | 590,000 |
Reported balance
After 2021-02-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-01 · Grant · Acquired 140,000 · Balance 590,000 F2: Shares will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest and become exercisable annually over four years, subject to a continued service relationship with the Issuer on such vesting date.
F2: Shares will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2026 Filed May 14, 2026 20:10 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 6,518 | $0.00 | $0.00 |
DisclosureSEC source: 0001369067-26-000009 · wk-form4_1778789440.xml · nonDerivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,100 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 13:54 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | PurchaseCommon Stock | 940 | $31.87 | $29,953.10 |
DisclosureSEC source: 0001369067-26-000006 · wk-form4_1773237273.xml · nonDerivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,582 Read SEC document |
| January 26, 2026 Filed Jan 28, 2026 21:11 UTC | Indivior Pharmaceuticals, Inc. INDV · Entity 4040 | GrantCommon Stock | 3,722 | $0.00 | $0.00 |
DisclosureSEC source: 0001369067-26-000004 · wk-form4_1769634705.xml · nonDerivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,642 F1 · shares: Reflects a grant of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the day immediately preceding the date of the first annual meeting of the Issuer's stockholders following the date of grant, subject to the Reporting Person's continued service to the Issuer on the vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:09 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $58.93 | $0.00 |
DisclosureSEC source: 0001179110-21-001250 · edgar.xml · derivative · entry 2 Kingsley Stuart A · CIK 0001369067 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 590,000 Underlying: Common Stock · 140,000 shares Expires 2031-02-01 F2 · derivative.exercise_date: Shares will vest and become exercisable quarterly over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:09 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-001250 · edgar.xml · nonDerivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,000 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU award will vest and become exercisable annually over four years, subject to a continued service relationship with the Issuer on such vesting date. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 20:33 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 429,684 | $0.00 Strike: $13.83 | $0.00 |
DisclosureSEC source: 0001179110-20-008345 · edgar.xml · derivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,684 Underlying: Common Stock · 429,684 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares will vest over four years, with 25% vesting on July 14, 2021 and the remainder vesting in 12 quarterly installments thereafter, subject to such individual's continued service through each such date. Read SEC document |
| May 20, 2020 Filed May 21, 2020 20:42 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (right to buy) · Derivative | 20,316 | $0.00 Strike: $19.68 | $0.00 |
DisclosureSEC source: 0001179110-20-006435 · edgar.xml · derivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,316 Underlying: Common Stock · 20,316 shares Expires 2030-05-20 F1 · derivative.exercise_date: This option vests monthly over three (3) years, with the first monthly amount vesting on June 20, 2020. Read SEC document |
| June 08, 2018 Filed Jun 11, 2018 20:34 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 12,700 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001171843-18-004583 · formfour.xml · derivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,700 Underlying: Common Stock · 12,700 shares Expires 2028-06-07 F1 · derivative.exercise_date: The options were granted on June 8, 2018 and the shares underlying this option will vest 100% at the earlier of (i) June 8, 2019 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 20:20 UTC | Protara Therapeutics, Inc. PRTO · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 6,666 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001171843-17-003748 · formfour.xml · derivative · entry 1 Kingsley Stuart A · CIK 0001369067 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,666 Underlying: Common Stock, $0.001 par value · 6,666 shares Expires 2027-06-19 F1 · derivative.exercise_date: The options were granted on June 20, 2017 and the shares underlying this option will vest 100% at the earlier of (i) June 20, 2018 and (ii) the Issuer's next annual meeting of stockholders. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 19:02 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantStock Option (right-to-buy) · Derivative | 70,265 | $0.00 Strike: $52.70 | $0.00 |
DisclosureSEC source: 0001179110-17-003717 · edgar.xml · derivative · entry 2 Kingsley Stuart A · CIK 0001369067 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,265 Underlying: Common Stock · 70,265 shares Expires 2027-03-01 F2 · derivative.exercise_date: The option vests in forty-eight equal installments beginning April 1, 2017. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 19:02 UTC | MEDICINES CO /DE MDCO · Entity 152552 | GrantCommon Stock | 11,386 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-003717 · edgar.xml · nonDerivative · entry 1 Kingsley Stuart A · CIK 0001369067 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,386 F1 · shares: Shares of restricted stock vest in 25% increments on each anniversary of the date of grant, until fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.